COVID-19大流行导致后勤限制时期显著颈动脉狭窄治疗的优化
回顾性分析2018年9月至2023年3月连续318例显著颈动脉狭窄患者,分COVID前(CEA优先)、COVID期间(CAS优先)和COVID后(个体化)三个1.5年时段。CAS与CEA在30天内卒中、短暂性脑缺血发作或死亡复合终点上无显著差异,CAS在COVID前和COVID后期间再狭窄率显著更低。作者认为结果可能支持无相关禁忌时CAS优先,建议多学科团队讨论。
要点
- CAS与CEA在30天卒中、短暂性脑缺血发作或死亡复合终点上无显著差异
- 再狭窄率在COVID前和COVID后期间CAS显著低于CEA
- 作者认为无相关禁忌时可能支持CAS优先策略,建议多学科团队讨论
核心结论
- CAS与CEA在显著颈动脉狭窄患者中于COVID-19大流行前、期间和后的结局相当。
- CAS在COVID前和COVID后期间再狭窄率方面优于CEA。
- 作者认为结果可能支持在无相关禁忌时采用CAS优先策略,且不使患者暴露于开放手术相关并发症,建议多学科团队讨论。
研究设计与样本
- 回顾性分析2018年9月至2023年3月连续接受CEA或CAS治疗的显著颈动脉狭窄患者。
- 每连续1.5年为一个治疗时期:COVID前(CEA优先策略)、COVID期间(CAS优先策略)和COVID后(个体化方案)。
- 共纳入318例患者,CEA组137例(COVID前55例、COVID期间36例、COVID后46例),CAS组181例(COVID前38例、COVID期间59例、COVID后84例)。
主要发现
- 主要终点(30天内卒中、短暂性脑缺血发作或死亡复合终点)在CEA组COVID前、期间、后分别为5.5%、0%、2.2%,CAS组分别为0%、1.7%、3.6%(P分别为0.27、1.00、1.00)。
- 总体技术成功率CEA为100%,CAS为99.4%(P=1.00)。
- 再狭窄率是唯一在COVID前和COVID后期间CAS显著优于CEA的次要结局指标(CEA vs CAS,12.7% vs 7.9%,P=0.03;23.9% vs 4.8%,P=0.03)。
- 大流行期间从就诊到治疗的间隔无显著差异。
临床怎么用
- 作者认为结果可能支持在无相关禁忌时采用CAS优先策略,且不使患者暴露于开放手术相关并发症。
- 建议多学科团队讨论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 confronted medical care with many challenges. During the pandemic, several resources were limited resulting in renouncing or postponing medical care like carotid endarterectomy (CEA) for patients with significant carotid artery stenosis. Although according to international guidelines CEA is the first choice, carotid artery stenting (CAS) could potentially be a reasonable alternative especially during logistical restraints. PURPOSE: To evaluate outcomes of CAS versus CEA before, during and after the COVID-19 pandemic. Our hypothesis was that a CAS first approach yielded comparable outcomes compared to a CEA first approach. METHODS: Retrospective analysis of consecutive patients with significant carotid artery stenosis treated with CEA or CAS between September 2018 and March 2023. Each consecutive period of 1.5 year marked a new (treatment) period: pre-COVID (CEA first strategy), during COVID (CAS first strategy) and post-COVID (patient-tailored approach). Primary outcome was the composite endpoint of stroke, transient ischemic attack or death within 30 days. Secondary outcome consisted of the rate of technical success, cerebral hyperperfusion syndrome, myocardial infarction or other cardiac complications needing intervention, bleeding of the surgical site needing intervention, nerve palsy, unintended IC admission, pseudoaneurysm, restenosis, or occlusion. RESULTS: A total of 318 patients were included. Out of 137 patients treated with CEA, 55, 36 and 46 were treated pre-COVID, during COVID and post-COVID, respectively. Out of 181 CAS procedures, 38, 59 and 84, respectively, were performed in each time period. Primary outcome occurred in 5.5%, 0% and 2.2% in the CEA group and 0%, 1.7% and 3.6% in the CAS group (P = 0.27; P = 1.00; P = 1.00, respectively). Overall technical success was 100% for CEA and 99.4% for CAS (P = 1.00). Rate of restenosis was the only secondary outcome measure which was significantly better after CAS compared to CEA in the pre- and post-COVID period (CEA vs. CAS, 12.7% vs. 7.9%, and 23.9% vs. 4.8% with a P-value of 0.03 and 0.03, respectively). Hospital presentation to treatment interval did not differ significantly during the pandemic. CONCLUSIONS: Outcomes were comparable between CAS versus CEA in patients with significant carotid artery stenosis before, during and after the COVID-19 pandemic. CAS showed better results in terms of other complications (i.e., restenosis rate) in the pre- and post-COVID period compared to CEA. Our results may support a CAS first approach when no relevant contra-indications exist without exposing the patient to complications associated with an open surgical approach. Discussion in a multidisciplinary team is advised.
引用
- Kök M, de Heide EJ, Hellegering J, et al. Optimizing Treatment of Significant Carotid Artery Stenosis in Times of Logistic Restraints as a Result of COVID-19 Pandemic. Ann Vasc Surg. 2024. PMID: 39009113. doi:10.1016/j.avsg.2024.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。